Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H18N2O4S |
| Molecular Weight | 334.39 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC1=CC=C(C=C1)C(=O)NS(=O)(=O)C2=CC=C(N)C=C2
InChI
InChIKey=FBFBRAFXKGRRHI-UHFFFAOYSA-N
InChI=1S/C16H18N2O4S/c1-11(2)22-14-7-3-12(4-8-14)16(19)18-23(20,21)15-9-5-13(17)6-10-15/h3-11H,17H2,1-2H3,(H,18,19)
| Molecular Formula | C16H18N2O4S |
| Molecular Weight | 334.39 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sulfaproxyline is a sulfonamide derivative patented by J. R. Geigy A.-G. as an antibiotic, useful in the treatment of urinary tract infections. In preclinical models, sulfaproxyline is effective against staphylococci infection in guinea pigs. Bisulfon D, a drug product comprising the combination of sulfaproxyline and sulfamerazine has been used for the treatment of urinary tract infections in the puerperium.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:10:55 GMT 2025
by
admin
on
Mon Mar 31 18:10:55 GMT 2025
|
| Record UNII |
YR841R53VW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C255
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
||
|
NCI_THESAURUS |
C29739
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000083276
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
116-42-7
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
204-140-5
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
301
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
DTXSID70861746
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
C72855
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
SUB10722MIG
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107520
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
C052571
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
120646
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
YR841R53VW
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | |||
|
m10337
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
67002
Created by
admin on Mon Mar 31 18:10:55 GMT 2025 , Edited by admin on Mon Mar 31 18:10:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |